An observational study in Regular Low-Frequency Hemoperfusion, Medium- to Long-Term Prognosis and Maintenance Dialysis Patients, sponsored by Yunfeng Xia. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-16.
Sponsored by Yunfeng Xia · Observational
Objective: To investigate the effect of regular low-frequency hemoperfusion on all-cause mortality and cardiovascular/cerebrovascular mortality risk in maintenance hemodialysis (MHD) patients.
Methods: Data from MHD patients over the past 10 years at our blood purification center were retrospectively collected. Patients were divided into a hemoperfusion group (receiving regular low-frequency hemoperfusion once monthly) and a non-hemoperfusion group. Propensity score matching (PSM) was used to balance baseline characteristics. Differences in cumulative all-cause and cardiovascular/cerebrovascular mortality between the two groups before and after matching were compared. A competing risk model was employed to analyze mortality risk.
Clinical and laboratory data were collected for all enrolled patients. These included age, sex, underlying medical conditions, dialysis vintage, blood pressure, serum albumin, hemoglobin, platelet count, C-reactive protein (CRP), serum calcium, serum phosphorus, intact parathyroid hormone (iPTH), total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL), triglycerides, and serum β2-microglobulin. Time-averaged mean values were calculated for blood pressure and laboratory parameters across the entire follow-up period. Data on cardiovascular/cerebrovascular death and all-cause mortality over the past ten years were also compiled.
Given the considerably larger size of the Hemoperfusion Group compared with the Non-Hemoperfusion Group, propensity score matching (PSM) was performed by specialized statisticians during data processing to balance baseline characteristics between the two groups. This approach enabled a systematic assessment of the effect of regular low-frequency hemoperfusion on cardiovascular/cerebrovascular and all-cause mortality in MHD patients.
Yunfeng Xia is the lead sponsor of 4 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients who received MHD treatment at the Hemodialysis Center of the First Affiliated Hospital of Chongqing Medical University from January 2015 to December 31, 2024. Included patients were aged ≥18 years, received dialysis three times a week (each session lasting 3-4 hours), had basically complete clinical and laboratory records, and were followed up at our center for at least 6 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
receive regular low-frequency hemoperfusion once monthly
not receive regular low-frequency hemoperfusion once monthly
Cardiovascular/Cerebrovascular Death
Time frame: 1, 3, 5, and 10 years
all-cause mortality
Time frame: 1, 3, 5, and 10 years
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Yunfeng Xia